(NASDAQ: EXAS) Exact Sciences's forecast annual revenue growth rate of 12.16% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Exact Sciences's revenue in 2025 is $2,758,867,000.On average, 7 Wall Street analysts forecast EXAS's revenue for 2025 to be $567,423,323,600, with the lowest EXAS revenue forecast at $565,272,275,999, and the highest EXAS revenue forecast at $569,115,555,349. On average, 7 Wall Street analysts forecast EXAS's revenue for 2026 to be $645,182,394,106, with the lowest EXAS revenue forecast at $630,472,423,505, and the highest EXAS revenue forecast at $660,657,676,980.
In 2027, EXAS is forecast to generate $721,075,551,558 in revenue, with the lowest revenue forecast at $713,356,485,662 and the highest revenue forecast at $728,794,617,454.